ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

585
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
21 Sep 2025 10:05

HK Connect Flows Weekly (Sep 19th): Alibaba, Beigene, China Pacific Insurance

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Alibaba, Beigene, China Pacific Insurance, Duality...

Logo
582 Views
Share
19 Sep 2025 10:16

Hong Kong Buybacks Weekly (Sep 19th): Tencent, Hang Seng Bank, Mgm China

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Tencent (700 HK),...

Logo
493 Views
Share
12 Sep 2025 15:20

The Heat Is On: News Flow and Sentiment in CHINA / HONG KONG (September 11)

HSTECH index is showing increasing strength as Hong Kong continues it Secular Bull Market.  Continued strong market breadth indicates both...

Logo
680 Views
Share
12 Sep 2025 09:54

Hong Kong Buybacks Weekly (Sep 12th): Tencent, Hang Seng Bank, China Hongqiao

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Tencent (700 HK),...

Logo
534 Views
Share
bullishMetaplanet
08 Sep 2025 08:08

ECM Weekly (8 September 2025)- Metaplanet, Lifedrink, Koei, Hesai, Orion, Myungin, Hesai, Chery

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Logo
703 Views
Share
x